Navigation Links
The Deal Names Abbott Top Dealmaker for Second Consecutive Year
Date:11/19/2009

ABBOTT PARK, Ill., Nov. 19 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the second consecutive year. The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective strategic use of acquisitions and divestitures since January 2006.

Over the past decade, Abbott has reshaped its business portfolio with a focus on high-growth, innovation-driven businesses with market-leading potential. In the past 12 months, Abbott has initiated more than $10 billion in strategic transactions that have diversified product and pipeline portfolios, added new technology and accelerated expansion into key global emerging markets.

"Abbott has a strong and successful track record of acquiring small- to mid-size companies and technologies with the potential for long-term growth and market leadership," said Miles D. White, chairman and chief executive officer, Abbott. "Over the past 12 months, Abbott has announced seven strategic acquisitions that will enhance the diversity of our portfolio and expand our global reach to deliver industry-leading returns to our shareholders."

In 2009, Abbott has:

  • Announced the purchase of a novel compound in development to treat chronic pain, enhancing Abbott's early-stage pharmaceutical pipeline.
  • Announced its intent to acquire Solvay Pharmaceuticals, complementing its existing portfolio and expanding infrastructure in key global emerging markets.
  • Acquired Evalve, entering the emerging field of non-surgical treatment for heart valve repair.
  • Purchased Visiogen, gaining a next-generation technology to treat cataracts.
  • Announced plans to acquire the nutrition business of Wockhardt, Ltd., positioning Abbott to be a leader in India.
  • Purchased Advanced Medical Optics, gaining immediate leadership in the multi-billion dollar eye care market.
  • Enhanced its leading-edge technology in diagnostic testing and surveillance with the addition of award-winning IBIS Biosciences.

Other key acquisitions within the timeframe for award consideration:

  • Purchased Kos Pharmaceuticals, immediately enhancing Abbott's existing franchise and portfolio strength in the $20 billion lipid management market with Niaspan® (niacin extended-release tablets), a best-in-class therapy for raising HDL "good" cholesterol.
  • Acquired Guidant's vascular business, providing Abbott with the current market-leading drug-eluting stent, XIENCE V(TM), and the world's first bioabsorbable drug-eluting stent to enter clinical trials.

The Deal's readers rated Abbott best on all four of its award criteria: choice of targets and strategy; price paid (or received) compared to value; execution, including integration; and overall quality of the deal team. Companies considered for the survey have a market capitalization of $5 billion or more as of June 30, 2009, and closed the highest number and dollar value of acquisitions and divestitures in the past three and a half years.

About The Deal LLC

The Deal LLC, (www.thedeal.com), is a diversified media company that is the authoritative voice of the deal economy. The Deal LLC serves the global deal community - corporate and financial dealmakers, advisers and institutional investors - by providing business and financial news and information that offers fresh insights on the deal economy, a set of interrelated activities, focused on dealmaking of all kinds, whose purpose is to generate corporate growth in a continually changing global market. The Deal LLC offers a comprehensive line of print and electronic products - The Deal, The Daily Deal and TheDeal.com - and live annual events including Private Capital Symposium, Distressed Investing Forum, Corporate Dealmaker Forum and M&A Outlook. The Deal LLC, a privately held company, is owned by private investment funds, including U.S. Equity Partners LP, sponsored by Wasserstein & Co. LP.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEV Technologies Names Christopher M. Owens President, Chief Executive Officer
2. AMD LASERS Names Dr. James Jesse as Medical Director
3. Arcadia Resources Names Stephen Goldsmith to Board of Directors
4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
5. Codexis Names Fernando Valle Research Fellow
6. Veridiam Names Robert Mazzacavallo New CFO
7. Hospira Names Daphne E. Jones Chief Information Officer
8. Premier Research Names Bernard Sweeney as Executive Director, Medical Devices
9. American Hospital Association (AHA) Names OnBase RACTrac Compatible
10. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
11. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... June 23, 2016  Experian Health, the ... transforming the patient payment and care experience, ... new products and services that will enhance ... cycle offerings. These award-winning solutions will enable ... remain compliant in an ever-changing environment and ...
Breaking Medicine Technology:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):